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2-Pyridylquinolone Antimalarials with Improved Antimalarial 
Activity and Physicochemical Properties 
Sitthivut Charoensutthivarakul,a W. David Hong,a Suet C. Leung,a Peter D. Gibbons, a Paul T.P. 
Bedingfield,b Gemma L. Nixon,a Alexandre S. Lawrenson,a Neil G. Berry,a Stephen A. Ward,b 
Giancarlo A. Biaginib and  Paul M. O’Neill*a  
A series of 2-pyridylquinolones has been prepared in 5-7 steps and through lead optimisation, antimalarial activity as low as 
12 nM against Plasmodium falciparum (Pf) has been achieved. Compared with previous analogues in this series, selected 
molecules have improved solubility, a reduced potential for off-target toxicity and improved metabolic stability profiles. 
Docking studies performed with a homology model of the Pfbc1 complex target demonstrate a key role for the Tyr16 residues 
in the recognition of highly active quinolone based inhibitors. 
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Introduction  
 Malaria is caused by parasites of the genus Plasmodium which are widespread in tropical and subtropical regions of the world 
and is responsible for one million deaths every year1. Plasmodium falciparum is the most deadly form of the parasite transmitted to 
the human host by Anopheles mosquitoes2 and has developed resistance to many of the established classes of drugs3. Due to drug 
resistance, the discovery of novel drug candidates remains a top priority. The development of compounds focused on hitting new 
targets is seen as a viable way forward and is an established approach to avoid cross resistance with available antimalarials4. 
 There are a large number of recent studies based on the development of antimalarials with quinolone-related structures5-7. One 
of these programmes resulted in the discovery of ELQ-300, a selective cytochrome bc1 inhibitor now in pre-clinical development
8-
10. Our recent work has shown that inhibition of two mitochondrial enzymes in the electron transport chain – the cytochrome bc1 
complex and the recently identified PfNDH2 (Type II NADH:ubiquinone oxidoreductase)11, 12 – results in the collapse of the 
mitochondrial membrane potential and to the inhibition of de novo pyrimidine biosynthesis and ultimately parasite death13. Since 
effective dual inhibition of these proteins can be observed with the 2-aryl and 2-pyridylquinolone pharmacophore14a a number of 
inhibitors based on this structure have been identified. Two such lead compounds are CK-2-68 and SL-2-25 (1) – both of which 
confer potent nanomolar activity against asexual and liver stages of P. falciparum15, 16(Figure 1). Here, we describe further 
modifications of the quinolone A-ring and 2-pyridyl side chain with the aim of reducing lipophilicity in an attempt to provide 
compounds with improved activity/solubility profiles.  
 In order to increase polarity of our quinolone hit series we incorporated a hydroxyl group into the A-ring at one of the 6, 7 or 8-
positions. The inclusion of the hydroxyl group in the quinolone A-ring offered the option of exploring pro-drugs for the series by 
derivatisation to provide either phosphate or carbamate pro-drugs. Since the corresponding methoxy analogues were prepared en 
route to 23 - 25, these compounds were also screened against Plasmodium falciparum.   
Results and discussion 
 The synthesis of the methoxy and hydroxy series was accomplished in 5-7 steps from commercially available starting materials 
(see Scheme 1). Aldehyde 2, synthesised from corresponding boronic acid and aromatic halide in excellent yield (see supporting 
information), was utilised in a Grignard reaction to give alcohol 3 in 32-83% yields. Alcohol 3 was then oxidised using PCC to 
yield ketone 4 in good yields. Oxazole 6 was prepared in yields of 31-98% from the respective isatoic anhydride 5 which was 
synthesised by adding diphosgene into methoxy-substituted anthranilic acid17 (see Supporting information). Reaction of oxazole 6 
with ketone 4 in the presence of catalytic trifluoromethane sulfonic acid gave the desired quinolones 7 - 22 in 4-62% yields18. 
Some selected quinolones were further demethylated by adding BBr3 to obtain hydroxyl analogues 23-25 in 10-69 % yields. 
 From previous work, we had identified the p-OCF3 substituent on the D-ring provided excellent antimalarial activity. More 
recent work within our group on a related quinolone series revealed some advantages in 3,4-dichloro substitution (Figure 2) and 
for this reason we also briefly investigated this substitution pattern within the quinolone D-ring side-chain in analogues  16-17.  
Antimalarial activities 
 Analysis of the in vitro data reveals that excellent activity can be achieved by the introduction of a methoxyl group in the 7-
position (see Table 2, entries 9, 11 and 13). A clear trend is seen in the pyridyl series where 7-methoxy analogues provide optimal 
activity (see for example direct comparison of SL-2-25 and 9). In contrast, 5, 6 and 8-methoxy analogues of SL-2-25 resulted in a 
complete loss in antimalarial activity. 
 Hydroxyl substitution is less favorable when compared with their methoxylated products (see Table 2, for example comparison 
between 9 and 24). Some regioisomers of 9 (eg. 11 and 13) exhibit potent activity against the parasite. 3,4-Dichlorophenyl 
substitution also is tolerated as seen in 17 and 22 both of which show excellent antimalarial efficacy. Although 7-methoxy 
analogues provide the best activity, we also noted that analogues 18, 20 and 22, which lack this substituent, are potent nanomolar 
antimalarials. 
 Looking into their molecular structures, compound 9, 15, 16, and 21 containing a 7-OMe group and a similar para substitution 
side chain devoid of flexibility show low to moderate antimalarial activities. On the other hand, 11 – 14 and 17 - 20 containing 
meta substitution configured side chains exhibit good to outstanding efficacy against the 3D7 parasite strain. 
 Additionally, some selected compounds were tested against drug resistant strains of P. falciparum including chloroquine 
resistant W2 and atovaquone resistant TM90C2B (Table 3). Compound 11 and 13, both contain flexible side chains, showed 
excellent activities against both W2 and TM90C2B strains that are comparable to marketed drugs (chloroquine and atovaquone) 
and SL-2-25. Notably, against the atovaquone resistant strain TM90C2B both 11 and 13 express excellent activity and show no 
cross resistance with atovaquone. Both 11 and 13 were also tested against 3D7-yDHODH·GFP, a transgenic derivative of P. 
falciparum 3D7 containing yeast dihydroorotate dehydrogenase,14a,b and were shown to be inactive (IC50 >1 µM), consistent with 
these inhibitors targeting the electron transport chain of the parasite mitochondria. 
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Drug Solubility Profiles 
 The poor aqueous solubility associated with the 2- and 3-aryl/pyridyl quinolone series of antimalarial provides development 
challenges for this class of drug. Previous research indicates that quinolones generally have poor aqueous solubility due to planar 
aggregation via π-stacking of their ring system16. This interaction also leads to higher observed melting points19. Several strategies 
can be used to improve the solubility; here, we explored the incorporation of a polar head group with modification of the pyridyl 
side-chain geometry. For those derivatives expressing higher potency, a 96-well plate aqueous solubility assessment was 
performed19. The results are shown in Table 4. A clear relationship between melting point and solubility was observed. Compound 
18 had the best aqueous solubility amongst the selected quinolones that correlated with its low melting point. Although 3,4-
dichlorophenyl analogues (16, 17 and 22) gave excellent activity, it is worth noting that a high melting point is observed which 
possibly reflects a decrease in aqueous solubility. Inspection of the side chain suggests that the pyridyl function exclusively affects 
both antimalarial activity and solubility. The presence of the pyridyl substitution (3,5-disubstituted pyridyl) as in 11, 17 and 18 
gives excellent potency and a range of melting points that were significantly lower than SL-2-25’s. This relationship can be used 
within this compound class to compare solubility.  
Metabolic Stability Profiles 
 Selected potent quinolones were also profiled in microsomal stability assessment in human liver microsomes and rat 
hepatocytes. Human microsomal stability assessment shows how stable the drug is when enters CYP450 oxidation stage, while rat 
hepatocytic clearance shows the compound stability in both phase I and phase II metabolism20. Comparing 7-OMe (11 and 17) to 
7-H (18, 20, 22) analogues, 7-OMe compounds are more sensitive to CYP450 turnover, possibly as a result of 7-O-demethylation. 
3,4-Dichlorophenyl compounds (17, 22) are more stable in human microsomal media than their p-OCF3 counterparts; the reverse 
is seen in rat hepatocytes with greater stability observed for the latter p-substituent.  
Potential for Off-target bc1 Inhibition 
 Previous antimalarial projects that have focused on the development of bc1 inhibitors have had to be terminated because of 
safety concerns regarding cardiotoxicity21. Therefore, a bovine bc1 counterscreen was established to investigate potential 
mammalian mitochondrial toxicity22. Some highly potent compounds were assessed in vitro, using bovine heart bc1 inhibition as 
displayed in Table 6.  
 The single-point inhibition experiments were run at two different concentrations of select compounds – 100 nM and 1 µM. A 
low % inhibition represents that the compound is less active in the bovine heart bc1 screen. There is no obvious trend when 
comparing 7-H compounds to their 7-OMe counterparts Generally, the substitutions on pyridyl ring as in 11, 17 and 18 provide 
molecules with lower affinity for the mammalian bc1 target.  Further studies are required to examine how this relationships extends 
to human heart tissue derived isolated bc1 complexes. 
Molecular Modeling 
 We have recently shown that 4-(1H)-pyridones bind to the Qi site in cytochrome bc1.
23 Consequently molecular modeling 
studies were undertaken to provide insight as to how the compounds bind to this site. Shown in Figure 3 is the docking pose 
between 9 and a Plasmodium homology model of the yeast bc1 complex.  
 A homology model of cytochrome bc1 based on the primary sequence Q02768 and the 1NTK B. taurus bc1 complex template 
was created with the PHYRE online homology modelling tool24. The model was used to predict the binding of 9 within the Qi 
active site. 
 Using GOLD and the methods developed in our group25 compounds were docked into the binding site. We observed that our 
potent inhibitors, 9 and 17, were predicted to bind tightly to the Qi site with the average PLPscores of 64 and 61, respectively.   
 In line with previous bc1 crystal structures with molecules bound in the Qi site (GW844520, GSK932121
23, antimycin or 
NQNO26), it was found that the interaction of quinolones with the bc1 target also involved several interactions – polar and 
hydrophobic. These include a hydrogen bond between Asp218 and the quinolone’s NH group whilst there is another weak  
hydrogen bond between Ser196 and the carbonyl group, very similar to the interactions of GW844520, GSK93212123 and 
antimycin.26 Of particular importance is the hydrophobic interaction of 7-methoxy within a hydrophobic pocket created by 
Leu214, Ile22, Phe210 and Trp26. The pyridyl group of 9 forms π stacking interactions with Phe30 and His12 whilst the OCF3 
moiety appears to form hydrophobic contacts with Ile34 and Phe37, which is similar to the interaction of the pentyl moiety in 
antimycin and alkyl chain in NQNO with the same two residues. This latter interaction is likely to be an important factor in 
providing extra levels of antimalarial activity as seen for 9, 11, 13 and 17.  
Conclusion 
 A 5-7 step synthesis of an array of 2-pyridylquinolones with potent antimalarial activity has been described. Subtle changes to 
the geometry of the side chain have a profound effect on the inherent antimalarial activity, physicochemical, metabolic and bc1 
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inhibitory profiles of related quinolone analogues.  In terms of balance of properties, analogues 17 and 18 have improved 
properties over the initial lead compound with a reduced propensity for off-target mammalian bc1 inhibition coupled with 
improved solubility/ metabolic stability. These observations encourage selection of molecules in this class for additional in vivo 
PK and mouse activity assessment in the near future. 
Experimental 
 Air- and moisture-sensitive reactions were carried out in oven-dried glassware, sealed with rubber septa, under nitrogen from a 
balloon. Air- and moisture-sensitive liquids and reagents were transferred via syringe. Reactions were stirred using Teflon-coated 
magnetic stir bars. All commercial reagents were used without further purifications. NMR spectra were recorded in CDCl3 or 
DMSO-d6 on a Brucker AMX400 spectrometer (
1H 400 MHz, 13C 100 MHz). Chemical shifts (δ) were expressed in ppm relative 
to tetramethylsilane (TMS) as an internal standard. J values are in hertz (Hz) and the splitting patterns were designed as follows: s, 
singlet; d, doublet; t, triplet; q, quartet; dd, double doublet; m, multiplet. Mass spectra were recorded on either a Micromass LCT 
Mass Spectrometer using electrospray ionisation (ESI) or Trio-1000 Mass Spectrometer using chemical ionisation (CI). Elemental 
analysis (%C, %H, %N) was performed in the University of Liverpool microanalysis laboratory. All melting points were 
determined with Gallenkamp melting point apparatus and were uncorrected. See supporting information for experimental and data 
on all intermediates. 
General procedure for the synthesis of quinolones  
 To a solution of o-oxazoline-substituted anilines (1.1 eq, 1.1 mmol) and ketones (1.0 eq, 1.0 mmol) in dry n-butanol (15 mL) 
was added trifluoromethane sulfonic acid (20 mol %) and the mixture was stirred under reflux (135 oC) for 24 hours. The reaction 
was cooled to room temperature and the solvent was evaporated under vacuum. Saturated sodium carbonate solution (20 mL) was 
added. The aqueous solution was extracted with EtOAc (3 x 20 mL), washed with brine, dried over MgSO4, and concentrated 
under vacuum. The crude mixture was purified by column chromatography to give quinolones. 
 9: white solid (yield 51%); mp 324 -325 oC; 1H NMR (400 MHz, DMSO) δ 11.60 (s, 1H, NH), 8.88 (d, J = 1.9 Hz, 1H), 8.34 
(d, J = 8.8 Hz, 2H), 8.24 (d, J = 8.2 Hz, 1H), 8.15 (dd, J = 8.2, 1.9 Hz, 1H), 8.04 (d, J = 9.0 Hz, 1H), 7.55 (d, J = 8.8 Hz, 2H), 6.99 
(d, J = 2.3 Hz, 1H), 6.93 (dd, J = 9.0, 2.3 Hz, 1H), 3.84 (s, 3H, 7-OMe), 1.93 (s, 3H, 3-Me). 13C NMR (101 MHz, DMSO) δ 162.1, 
155.4, 149.8, 138.5, 130.3, 129.2, 129.1, 121.7, 121.6, 120.4, 118.0, 115.2, 113.6, 99.0, 55.7, 12.3. ES HRMS: m/z calculated for 
C23H18N2O3F3 ([M+H]
+) 427.127, found 427.129. 
 11: white solid (yield 34%); mp 255 -258 oC; 1H NMR (400 MHz, DMSO) δ 11.57 (s, 1H, NH), 9.10 (d, J = 2.2 Hz, 1H), 8.80 
(d, J = 2.2 Hz, 1H), 8.35 (t, J = 2.2 Hz, 1H), 8.05 (d, J = 9.0 Hz, 1H), 8.01 (d, J = 7.9 Hz, 2H), 7.55 (d, J = 7.9 Hz, 2H), 6.97 (d, J 
= 2.3 Hz, 1H), 6.93 (dd, J = 9.0, 2.3 Hz, 1H), 3.84 (s, 3H, 7-OMe), 1.94 (s, 3H, 3-Me). 13C NMR (101 MHz, DMSO) δ 176.6, 
162.1, 148.9, 148.7, 144.2, 141.7, 136.1, 135.1, 134.3, 131.4, 129.6, 127.3, 122.1, 118.1, 115.3, 113.6, 99.0, 55.7, 12.3.ESI 
HRMS: m/z calculated for C23H18N2O3F3 ([M+H]
+) 427.127, found 427.127. 
 13: white solid (yield 34%); mp 245 -247 oC; 1H NMR (400 MHz, DMSO) δ 11.56 (s, 1H, NH), 8.89 (d, J = 5.0 Hz, 1H), 8.34 
(d, J = 8.0 Hz, 2H), 8.22 (br s, 1H), 8.06 (d, J = 9.0 Hz, 1H), 7.60 (dd, J = 5.0, 1.5 Hz, 1H), 7.53 (d, J = 8.0 Hz, 2H), 7.00 (d, J = 
2.4 Hz, 1H), 6.94 (dd, J = 9.0, 2.4 Hz, 1H), 3.85 (s, 3H, 7-OMe), 1.93 (s, 3H, 3-Me). 13C NMR (101 MHz, DMSO) δ 176.6, 162.1, 
155.5, 150.4, 144.9, 144.2, 141.7, 137.7, 129.2, 127.3, 123.2, 121.6, 120.7, 118.1, 114.7, 113.7, 111.4, 99.1, 55.7, 12.2. ESI 
HRMS: m/z calculated for C23H18N2O3F3 ([M+H]
+) 427.127, found 427.127. 
 17: yellow solid (yield 17%); mp 290 -292 oC; 1H NMR (400 MHz, DMSO) δ 11.59 (s, 1H, NH), 9.15 (d, J = 2.0 Hz, 1H), 8.81 
(d, J = 2.0 Hz, 1H), 8.43 (t, J = 2.0 Hz, 1H), 8.22 (d, J = 2.2 Hz, 1H), 8.05 (d, J = 8.9 Hz, 1H), 7.91 (dd, J = 8.5, 2.2 Hz, 1H), 7.82 
(d, J = 8.5 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 6.94 (dd, J = 8.9, 2.4 Hz, 1H), 3.85 (s, 3H, 7-OMe), 1.93 (s, 3H, 3-Me). ESI HRMS: 
m/z calculated for C22H1162O2
35Cl2 ([M+H]
+) 411.067, found 411.067. 
 18: pale yellow solid (yield 54%); mp  217 – 220 oC; 1H NMR (400 MHz, DMSO) δ 11.77 (s, 1H, NH), 9.12 (d, J = 2.1 Hz, 
1H), 8.82 (d, J = 2.1 Hz, 1H), 8.38 (t, J = 2.1 Hz, 1H), 8.16 (dd, J = 8.3, 1.2 Hz, 1H), 8.01 (d, J = 8.8 Hz, 2H), 7.66 (ddd, J = 8.3, 
6.9, 1.5 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.34 (ddd, J = 7.9, 6.9, 1.2 Hz, 1H), 1.96 (s, 3H, 3-Me). 13C 
NMR (101 MHz, DMSO) δ 177.0, 148.9, 148.7, 144.7, 139.9, 136.0, 135.2, 134.2, 131.9, 131.4, 129.6, 125.4, 123.5, 123.3, 122.1, 
118.5, 115.6, 12.4. ESI HRMS: m/z calculated for C22H16N2O3F3 ([M+H]
+) 397.116, found 397.117. 
 20: off-white solid (yield 56%); mp  244 – 246 oC; 1H NMR (400 MHz, DMSO) δ 11.78 (s, 1H, NH), 8.90 (dd, J = 4.9, 0.7 Hz, 
1H), 8.35 (d, J = 8.9 Hz, 2H), 8.26 (br s, 1H), 8.16 (dd, J = 8.2, 1.1 Hz, 1H), 7.67 (ddd, J = 8.2, 6.8, 1.5 Hz, 1H), 7.63 (dd, J = 4.9, 
1.5 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 8.9 Hz, 2H), 7.34 (ddd, J = 7.8, 6.8, 1.1 Hz, 1H), 1.95 (s, 3H, 3-Me). 13C NMR 
(101 MHz, DMSO) δ 150.4, 144.1, 139.9, 131.9, 129.2, 125.4, 123.5, 123.3, 123.3, 123.2, 121.6, 120.7, 118.6, 115.0, 12.3. ESI 
HRMS: m/z calculated for C22H16N2O3F3 ([M+H]
+) 397.116, found 397.117.  
 22: a pale yellow solid (yield 25%); mp = 270 - 272 oC; 1H NMR (400 MHz, DMSO) δ 11.75 (s, 1H, NH), 9.15 (d, J = 2.1 Hz, 
1H), 8.82 (d, J = 2.1 Hz, 1H), 8.45 (t, J = 2.1 Hz, 1H), 8.22 (d, J = 2.2 Hz, 1H), 8.15 (dd, J = 8.0, 1.1 Hz, 1H), 7.91 (dd, J = 8.4, 
Page 4 of 13MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
  
2.2 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.66 (ddd, J = 8.0, 6.9, 1.5 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.33 (ddd, J = 8.0, 6.9, 1.1 Hz, 
1H), 1.95 (s, 3H, 3-Me). HRMS (CI): m/z calculated for C21H14N2O
35Cl2 ([M+H]
+) 381.056, found 381.055. 
 
Parasite Culture 
 Plasmodium blood stage cultures27 and drug sensitivity28 were determined by established methods. IC50s (50% inhibitory 
concentrations) were calculated by using the four-parameter logistic method (Grafit program; Erithacus Software, United 
Kingdom). 
Molecular Modeling 
 A homology model of P. falciparum cytochrome bc1 complex was constructed using the PHYRE online homology modelling 
program24. The P. falciparum cytochrome b primary sequence Q02768 was obtained from UNIPROT29 used as the query 
sequence. A one to one threading model was built using PHYRE and the model produced had a confidence score of 100%. The 
docking was performed using default settings in Gold with ten docking poses calculated for each quinolone.  
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Figure Legends 
 
 
Figure 1. The quinolone core structure and initial lead compounds CK-2-68 and SL-2-25 (1) – and their 
antimalarial activity  
 
Figure 2. Previous work on 4-trifluoromethoxybenzyl and 3,4-dichlorobenzyl analogues. 
 
Figure 3. In silico docking of 9 into the Plasmodium falciparum bc1 homology model. Protein rendered as a 
cartoon in cyan with residues rendered as sticks. 9 rendered as sticks (carbon – grey, hydrogen – white, oxygen –
red, nitrogen – blue, fluorine - cyan). Hydrogen bond indicated by black dashed line with distance given in 
Ångstrom. 
 
 
 
 
Scheme 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: (a) EtMgBr, THF,0 oC, under N2, 1 h (b) PCC, DCM, 2 h (c) 2-amino-2-methyl-propanol, ZnCl2, 
PhCl,135 oC (d) CF3SO3H, n-BuOH, under N2 ,130 oC ,24 h (e) BBr3, DCM, rt., overnight.  
 
Scheme 1. Synthesis of Quinolones. 
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Tables 
 
 
 
 
 
 
Table 1 Yields for the synthesis of quinolone 7-22. 
Compound R X No. of steps % Yield 3 % Yield 4 % Yield 6 % Yield 7-22 
7 
 
5-OMe 6 67 69 98 4 
8 
 
6-OMe 6 67 69 48 22 
9 
 
7-OMe 6 67 69 73 51 
10 
 
8-OMe 6 67 69 30 25 
11 
 
7-OMe 6 32 92 73 34 
12 
 
7-OMe 6 73 47 73 40 
13 
 
7-OMe 6 55 99 73 34 
14 
 
7-OMe 7 32 66 73 42 
15  7-OMe 6 37 97 73 62 
16 
 
7-OMe 6 83 69 73 23 
17 
 
7-OMe 6 65 33 73 17 
18  7-H 5 32 92 31 54 
19  7-H 5 73 47 31 55 
20  7-H 5 55 99 31 56 
21 
 7-H 5 37 97 31 62 
22 
 
7-H 5 65 33 31 25 
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Table 2 In vitro antimalarial Activities versus 3D7 P. falciparum , aqueous solubilities and melting points of quinolones 
Compound R X IC50 (nM) 3D7 ± SD Melting point 
SL-2-25 
 
7-H 54 ± 6 277 - 278 oC 
7 
 
5-OMe > 1000 ND 
8 
 
6-OMe > 1000 312 - 314 oC 
9 
 
7-OMe 14 ± 2 324 - 325 oC 
10 
 
8-OMe > 1000 182 - 185 oC 
11 
 
7-OMe 12 ± 3 255-258 oC 
12 
 
7-OMe 149 ± 5 200-204 oC 
13 
 
7-OMe 12 ± 3 245-247 oC 
14  7-OMe 150 ± 10 188-190 oC 
15 
 
7-OMe > 1000 255-258 oC 
16 
 
7-OMe 200 ± 10 268-270 oC 
17  7-OMe 18 ± 3 290-292 oC 
18 
 
7-H 41 ± 2 217-220 oC 
19 
 
7-H 390 ± 30 187-192 oC 
20  7-H 21 ± 5 244-246 oC 
21 
 
7-H > 1000 239-241 oC 
22  7-H 40 ± 4 270-272 oC 
23 
 
6-OH 326 ± 50 decomposed at 250oC 
24 
 
7-OH 202 ± 79 ND 
25 
 
8-OH > 1000 154 - 156 oC 
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Table 3. Drug resistant parasites inhibition profiles of selected quinolones 
Compound 
IC50 (nM) 
W2 
IC50 (nM) 
TM90C2B 
chloroquine 12.3 14.5 
atovaquone 0.3 9908 
SL-2-25 48 156 
11 4.0 7.2 
13 4.2 7.0 
 
Table 4. Selected compounds solubility profiles 
Compound Melting point 
Kinetic Solubility 
(µM) 
pH 1 pH 7.4 
SL-2-25 277 - 278 oC 3.2 <1 
9 324 -325 oC 2.6 <1 
11 255 -258 oC 7.8 <1 
13 245 -247 oC 120 <1 
17 290 -292 oC 15 14 
18 217 -220 oC 140 3.6 
20 244 -246 oC 79 2.1 
 
Table 5. Selected compounds metabolic stability profiles 
Compound 
Human Mics CLint 
(µL/min/mg) 
Rat Heps CLint 
(µL/min/106 cell) 
SL-2-25 20.6 ND 
11 25.9 1.2 
17 14 4.9 
18 12.5 1.8 
20 7.7 2.5 
22 5.6 9.9 
 
 
Table 6. Enzyme and parasite inhibition profiles of selected quinolones. 
Compound IC50 (nM) 3D7 
Bovine heart bc1 
(% inhibition at 100 nM) 
Bovine heart bc1 
(% inhibition at 1 μM) 
9 14 55 98 
11 12 19 81 
13 12 63 85 
17 18 13 20 
18 41 20 25 
20 21 52 81 
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IC50 (3D7) = 200 nM IC50 (3D7) = 70 nM
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